AstraZeneca deepens Summit ties on ADC-bispecific cancer combo testing pact

AstraZeneca and Daiichi Sankyo have signed a deal with Summit Therapeutics to test their ADC Datroway (datopotamab deruxtecan) alongside Summit's PD-1 x VEGF bispecific antibody ivonescimab in several tumour types, starting with a Phase III study in frontline triple-negative breast cancer. Daiichi and Summit will share trial costs, and each keeps rights to its own medicine. The pact follows AstraZeneca's $2bn equity investment in Summit for an estimated 12% stake and a separate deal on the CLDN18.2-targeting ADC sonesitatug vedotin combined with ivonescimab; ivonescimab is under US regulatory review in NSCLC with a PDUFA date of 14 November.